Healthcare and pharmaceutical deals are priced on licences and registrations, not on a generic diligence checklist.

When you acquire a hospital, a diagnostics chain, or a pharmaceutical distributor in the UAE, the cash flow you are paying for rests on a permission a regulator granted to someone else. A DHA facility licence in Dubai, a DOH operator licence in Abu Dhabi, and the personnel licences beneath them do not move because you signed a share purchase agreement. Change of control triggers review. The regulator can attach conditions, hold clearance past your funding window, or refuse it. Buyers who treat that approval as a closing formality are the ones who watch the price they negotiated evaporate between signing and completion.

Sequence works differently here than in a generic services acquisition. DHA and DOH examine the acquirer's fitness, the continuity of the medical director and licensed clinical staff, and whether the facility still meets the standard its licence was issued against. For anything touching drugs or devices, the reference point shifted at the end of 2025: the Emirates Drug Establishment (EDE) took over federal registration of pharmaceuticals and medical devices from MOHAP. A target's product registrations, import permissions, and pricing approvals now sit with EDE, and you inherit every gap in that file. Where registrations are held personally, tied to a founder who is about to exit, or due to lapse on transfer, the revenue attached to them is not yours until re-registration clears. That timeline belongs in the model, not in a footnote.

Mandatory insurance under DHA and DOH means most of a provider's revenue arrives through a handful of insurers and third-party administrators. So the questions that decide durability are commercial. How much of collections runs through the top three payers? What is the claim rejection rate, and is it drifting up as tariffs tighten? Are contract renewals annual, and do they reprice the procedures that carry the margin? A target reporting AED 90m of revenue with two payers behind 70% of it is a different risk than the same number spread across a broad book. Payer mix shapes the discount rate you should apply, and a buyer who ignores it is paying a strategic-asset price for a concentrated one.

This is where a pharma or life-sciences deal stops resembling a single-entity acquisition. You are not valuing a trading business as it stands today. You are valuing a portfolio of registered products, each with its own patent runway, EDE registration status, tender exposure, and substitution risk once a generic lands. Some SKUs are years from a competing molecule; others lose their protection inside the forecast period. A distribution agreement that looks like an annuity may carry a change-of-control clause that lets the principal walk when ownership shifts. Building that view means a longer diligence than a clinic acquisition, because the cash flows have to be projected product by product and then tested against the regulatory calendar. Collapse the portfolio into one growth rate and you will misprice it in both directions, overpaying for the declining lines and underpaying for the protected ones.

A comparable-multiple screen is a starting point, not an answer, when the underlying assets behave this differently. A DCF that models registration renewals, patent expiries, tariff steps, and payer repricing tells you what the business is actually worth to you, at your cost of capital, under your integration plan. IFRS carrying values are a further trap: goodwill and intangibles booked at a prior transaction rarely reflect current registration risk or the real economic life of a product line. The number that survives a buyer's analyst is the one built from the asset up, with each assumption you can defend when the room pushes back.

Our position on a healthcare or pharma transaction is that diligence drives the decision, not the appetite to close. Sometimes the finding is a registration gap that re-registration will fix and the deal proceeds on adjusted terms. Sometimes it is a payer contract or a patent cliff that says renegotiate the price, restructure the earn-out, or walk. We charge on the transaction, so our incentive is a deal that holds up two years after completion, not one that merely signs. If you are weighing a healthcare or pharmaceutical acquisition and want the regulatory and asset-level valuation done before you commit, start with Avior.